Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Rating of “Reduce” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has earned a consensus rating of “Reduce” from the ten brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and nine have issued a hold recommendation on the company.

A number of equities research analysts have issued reports on BAYRY shares. The Goldman Sachs Group initiated coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They set a “neutral” rating for the company. Bank of America raised shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th.

Bayer Aktiengesellschaft Stock Up 0.7 %

BAYRY stock opened at $7.51 on Wednesday. The business’s 50-day moving average price is $7.46 and its 200-day moving average price is $7.42. Bayer Aktiengesellschaft has a twelve month low of $6.82 and a twelve month high of $13.29. The company has a quick ratio of 0.86, a current ratio of 1.27 and a debt-to-equity ratio of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.25. The business had revenue of $12 billion during the quarter. Bayer Aktiengesellschaft had a positive return on equity of 16.96% and a negative net margin of 2.74%. As a group, research analysts predict that Bayer Aktiengesellschaft will post 1.38 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.